The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
This campaign is to raise awareness about the crucial role helmet usage plays in saving lives
Renalyx will continue operating as an independent unit within the group
Venus Remedies now has 29 active product approvals in Vietnam alone
Subscribe To Our Newsletter & Stay Updated
